Samsung Foundation Research Improves Pediatric Brain Tumor Outcomes

Medical research in South Korea is shifting its focus for pediatric brain tumor patients from basic survival to the long-term quality of life, according to reporting by the Korea JoongAng Daily. This transition marks a new era in pediatric oncology where the primary challenge is no longer simply whether a child survives, but how they can lead a fulfilling and independent life after treatment.

The effort is being driven by a large-scale research initiative funded by a 300 billion won ($202 million) donation from the families of the late Samsung Chairman Lee Kun-hee. The fund is dedicated to supporting pediatric cancer and rare disease research, enabling doctors to explore outcomes that were previously overlooked due to the urgency of life-saving interventions.

Focusing on Post-Survival Quality of Life

The shift in clinical focus is supported by improving survival statistics. While in the past only about half of pediatric brain tumor patients survived, current data indicates that more than two-thirds now survive and tend to live longer lives.

Because more children are surviving these diagnoses, researchers are now prioritizing the cognitive, emotional and physical tolls of treatment. Since 2022, a joint study involving eight institutions—including Seoul National University Hospital (SNUH), Samsung Medical Center, the National Cancer Center, and Yonsei Cancer Center—has been tracking long-term functional changes in patients before and after their treatment.

More children with brain tumors are now cured and living long lives. We’ve entered a new era where we contemplate how to improve patients’ quality of life after their survival.

Lee Joo-ho, professor of radiation oncology at Seoul National University Hospital

The project aims to create a comprehensive map of how brain functions shift during the course of treatment. By understanding these changes, medical teams hope to develop better strategies to help survivors regain their independence and integrate back into society.

Advancements in Precision Diagnosis

Beyond quality-of-life studies, the Lee Kun-hee donation has fueled the Stream (Strategic treatment and magic for pediatric cancers) program. Launched in earnest in 2023, this pediatric precision oncology program focuses on the precise diagnosis of pediatric solid tumors to deliver personalized treatments.

The program addresses a critical gap in pediatric care: the rarity of these diseases often makes research and diagnosis difficult compared to adult cancers. By gathering and analyzing genomic data across multiple hospitals, the initiative has enrolled about 700 patients over the last two-and-a-half years.

The scale of the database is significant. Korea sees roughly 500 new pediatric solid tumor cases annually, meaning more than half of all such cases in the country are now participating in the program. Researchers expect participation to reach about 70 percent of new patients as five additional hospitals join the effort in 2026.

Breakthroughs in Medulloblastoma Research

The funding has also supported specific breakthroughs in treating medulloblastoma, a cancerous tumor typically found in the cerebellum. Prof. Kim Seung-ki, a neurosurgeon at SNUH, and his team discovered a shared biological component among pediatric patients with this specific tumor.

This discovery is particularly vital because medulloblastoma has a high likelihood of metastasis through cerebrospinal fluid. According to Prof. Kim, the five-year survival rate for pediatric patients drops from over 80 percent to around 60 percent once the tumor spreads to other organs.

Current diagnostic tools, such as MRI and cerebrospinal fluid analysis, are often unable to detect micrometastasis—small clusters of cancer cells that are too few to be observed but can still compromise a patient’s prognosis. The research aims to enable earlier and more precise diagnoses, allowing doctors to adjust treatment approaches before the cancer spreads extensively.

These combined efforts in quality-of-life tracking, precision genomics, and biomarker discovery represent a holistic shift in how pediatric brain tumors are managed in South Korea, moving the goalpost from mere survival to lifelong wellness.